ClinicalTrials.gg
CompletedNCT03856879ACHIEVEUpdated Nov 10, 2026Results posted

High-quality COPD Care for People With Immune Dysfunction Through Proactive E-consults

An interventional study of Proactive E-consult in COPD and HIV/AIDS, sponsored by Seattle Institute for Biomedical and Clinical Research. Completed at 7 sites in United States. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Seattle Institute for Biomedical and Clinical Research · Not applicable, Interventional, and Health services research

How we know

Updated Nov 10, 2026Results postedStudy documents posted+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
346
Allocation
Randomized
Ages
18 Years to 89 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 139 open to participants now, 174 under way, 21 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.

Enrollment
294th of 1,039
346 · median 100
Started
2019
with 57 others
No phase
395 of 1,280
52 open now
Registered
908th of 1,280
by date

Among the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 294th largest by enrollment of the 1,039 interventional ones that give a count, is one of 58 that started in 2019, is one of 395 with no phase, and was the 908th registered.

Pulmonary Disease, Chronic Obstructive

5,529 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

139 of the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:

134 more — sign in →

All 139 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 89 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, or all of them as a file.
02

Study summary

This study examines an intervention to promote effective, evidence-based care and de-implement inappropriate therapies for COPD in HIV-infected (HIV+) patients. The intervention facilitates specialist support of primary care, which includes infectious disease (ID) physicians who serve as the primary care providers (PCP) for their HIV+ patients in the ID clinic. Rather than relying on referral-driven specialty care which may be a barrier to access, pulmonologists will proactively support ID providers to manage a population of HIV+ patients with COPD, delivering real-time evidence-based recommendations tailored to the individual HIV+ patient in the form of an E-consult.

Read the detailed description

Emerging data support that barriers to high quality COPD care are likely accentuated in HIV+ persons. Taken together, decreased recognition of smoking, lack of referral for pulmonary evaluation, worse symptoms and greater exacerbation rates point towards low quality of care for COPD in HIV+ patients. Our preliminary data supports that COPD is inadequately managed in HIV+ patients. These data demonstrate that current management of COPD in HIV+ patients do not adhere to guidelines, that ICS may be over-prescribed and long-acting bronchodilators under-utilized, and support the need to improve evidence-based COPD care in HIV+ patients. Appropriate use of COPD therapies is particularly important for HIV+ patients, as side effects and toxicities could be more harmful in HIV+ patients, given their concomitant multimorbidity and polypharmacy. In summary, an intervention to improve the evidence-based delivery of COPD care can improve outcomes for HIV+ patients. Benefits may extend beyond COPD-related measures. Appropriate use of COPD controller medications can decrease symptoms and exacerbations, and improve health-related quality of life. Our proposed study to has a high potential to substantially improve the quality of care for COPD and patient-centered outcomes for a large number of HIV+ Veterans.

This study tests an intervention to promote effective, evidence-based care and de-implement inappropriate therapies for COPD in HIV+ patients. The intervention facilitates specialist support of primary care, which includes infectious disease (ID) physicians who serve as the primary care providers (PCP) for their HIV+ patients in the ID clinic. Rather than relying on referral-driven specialty care, which may be a barrier to access, pulmonologists will proactively support ID providers to manage a population of HIV+ patients with COPD, delivering real-time evidence-based recommendations tailored to the individual HIV+ patient. The investigators will leverage the Department of Veterans Affairs (VA) clinical and informatics infrastructures to communicate between intervention-team members developing the recommendations (using VA Extension for Community Health Outcomes [ECHO]) and to patients' clinical providers through the electronic health record (EHR) as an E-consult. To limit the burden on the provider, the intervention team will draft recommendations as preliminary orders for providers to review. To preserve their autonomy, the provider has the discretion to endorse (sign), modify or cancel the orders.

This study uses a two-arm cluster randomized controlled trial intervention design grounded in the chronic care model with outcomes evaluated using the RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance) framework. The investigators will evaluate barriers and facilitators of optimal COPD care for HIV+ patients, and of effective adoption, implementation and maintenance of the proactive E-consult program, guided by the Consolidated Framework for Implementation Research (CFIR).

This study involves the recruitment and enrollment of two populations: providers and patients. Providers will be recruited at the beginning of the study; providers that enroll will be randomly chosen to either provide usual care (control) or to receive E-consults for their HIV+ patients with COPD (intervention). Patients of enrolled providers will be recruited after attending an appointment with their provider. Enrolled patients will be asked to complete a set of surveys, and some patients will be offered the opportunity to participate in an interview about their care.

03

Conditions studied

  • COPD
  • HIV/AIDS

Keywords

  • Chronic obstructive pulmonary disease
  • intervention studies
  • randomized controlled trial
  • provider satisfaction
  • patient satisfaction
  • E-consult
04

Who can participate

Ages eligible
18 Years to 89 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Providers:

  • Outpatient infectious disease providers at one of the seven local sites participating in this study.

Patients:

  • + patients with treated by providers enrolled in the study.

Exclusion criteria

Exclusion Criteria:

Providers:

  • Trainees

Patients:

  • Significant cognitive dysfunction, language barriers or severe psychiatric disorder, impairing ability to participate in surveys and interviews.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
346 participants (actual)

Study arms

  • No intervention
    Usual care

    Providers in this arm will provide usual care to their HIV+ patients with COPD.

  • Experimental
    Proactive E-consult

    Providers in this arm will receive proactive E-consults with expert recommendations for COPD care prior to appointments with HIV+ patients with COPD.

    Behavioral: Proactive E-consult

Interventions

  • BehavioralProactive E-consult

    E-consult recommendations and orders will be developed by a panel of pulmonologists and will address a range of care elements for patients with COPD.

06

What researchers measure

Primary outcomes

  1. % of COPD Care Recommendations Received by Patients of Enrolled Providers

    % of COPD care recommendations received by the patient, examined collectively for each patient and individually by type of recommendation (e.g. use of spirometry, long acting bronchodilator, smoking cessation, vaccination, etc.) to assess the overall quality of COPD care. We will report percentage of actionable care recommendations received by the patient out of the total recommendations sent across all patients, using "Number" as the measure type.

    Time frame: Within 6 months following provider/patient appointment

Secondary outcomes

  1. Patient Health-related Quality of Life

    Patient-reported health-related quality of life on the Medical Outcomes 12-item short form (SF-12), a patient self-report survey. This survey is a 12-item scale with two subscales (mental and physical components). Summary scores range from 0-100, with higher scores reflecting better health.

    Time frame: 6 weeks following provider/patient appointment

Other outcomes

  1. HIV Provider Satisfaction With Specialty-care Support

    Baseline and follow-up self-report surveys (all participating providers) and interviews (sample of providers)

    Time frame: Baseline: prior to intervention roll-out. Follow-up: after exposure to intervention (defined as having received at least 2 E-consults), up to 3 years.

07

Results

Posted Nov 10, 2026
Limitations and caveats
Nothing to report at this time. Study limitations will be explained fully in future publication(s).

Participant flow

Participant flow — Overall Study
MilestoneUsual Care (Patients)Proactive E-consult (Patients)Usual Care (Providers)Proactive E-consult (Providers)
Started1401303541
Completed1401303541
Not completed0000

Outcome measures

Primary% of COPD Care Recommendations Received by Patients of Enrolled Providers

% of COPD care recommendations received by the patient, examined collectively for each patient and individually by type of recommendation (e.g. use of spirometry, long acting bronchodilator, smoking cessation, vaccination, etc.) to assess the overall quality of COPD care. We will report percentage of actionable care recommendations received by the patient out of the total recommendations sent across all patients, using "Number" as the measure type.

Time frame:
Within 6 months following provider/patient appointment
Reported as:
Number · Percentage of recommendations received
% of COPD Care Recommendations Received by Patients of Enrolled Providers
Percentage of recommendations receivedUsual Care (Patients)Proactive E-consult (Patients)
% of COPD Care Recommendations Received by Patients of Enrolled Providers2345
SecondaryPatient Health-related Quality of Life

Patient-reported health-related quality of life on the Medical Outcomes 12-item short form (SF-12), a patient self-report survey. This survey is a 12-item scale with two subscales (mental and physical components). Summary scores range from 0-100, with higher scores reflecting better health.

Time frame:
6 weeks following provider/patient appointment

Results for this outcome have not been posted.

Other pre-specifiedHIV Provider Satisfaction With Specialty-care Support

Baseline and follow-up self-report surveys (all participating providers) and interviews (sample of providers)

Time frame:
Baseline: prior to intervention roll-out. Follow-up: after exposure to intervention (defined as having received at least 2 E-consults), up to 3 years.

Results for this outcome have not been posted.

Adverse events

Collected over Within 1 year following index date. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Usual Care (Patients)9/140 (6.4%)38/140 (27.1%)33/140 (23.6%)
Proactive E-consult (Patients)8/130 (6.2%)26/130 (20%)25/130 (19.2%)
Most frequent serious events
Showing 10 of 37
Most frequent serious events
EventUsual Care (Patients)Proactive E-consult (Patients)
Multiple System InvolvementGeneral disorders14/14011/130
COPD ExacerbationRespiratory, thoracic and mediastinal disorders4/1405/130
Suicidal IdeationPsychiatric disorders5/1402/130
PneumoniaRespiratory, thoracic and mediastinal disorders3/1401/130
SepsisRespiratory, thoracic and mediastinal disorders0/1402/130
Shortness of BreathRespiratory, thoracic and mediastinal disorders0/1402/130
Chest PainCardiac disorders2/1401/130
Bone FractureMusculoskeletal and connective tissue disorders2/1400/130
Respiratory Distress/FailureRespiratory, thoracic and mediastinal disorders2/1401/130
UTIRenal and urinary disorders2/1400/130
Most frequent other events
Showing 10 of 39
Most frequent other events
EventUsual Care (Patients)Proactive E-consult (Patients)
Multiple System InvolvementGeneral disorders8/1404/130
COVID-19 Infection/SymptomsRespiratory, thoracic and mediastinal disorders2/1406/130
Skin Rash/DiscomfortSkin and subcutaneous tissue disorders1/1405/130
Back/Neck PainMusculoskeletal and connective tissue disorders4/1400/130
Leg/Knee PainMusculoskeletal and connective tissue disorders4/1402/130
Ankle/foot PainMusculoskeletal and connective tissue disorders2/1403/130
CoughRespiratory, thoracic and mediastinal disorders1/1403/130
Shortness of BreathRespiratory, thoracic and mediastinal disorders3/1402/130
BronchitisRespiratory, thoracic and mediastinal disorders3/1401/130
Ostomy Bag Leak/Suture RemovalGastrointestinal disorders0/1402/130

Baseline characteristics

Our baseline analysis describes patients that were enrolled in the usual care or proactive E-consult arms and providers who had proactive E-consults for their patients.

Age, Categorical
Age, Categorical(Participants)Usual Care (Patients)Proactive E-consult (Patients)Usual Care (Providers)Proactive E-consult (Providers)Total
<=18 years00000
Between 18 and 65 years68641818168
>=65 years726616145
Age, Continuous
Age, Continuous(Years)Usual Care (Patients)Proactive E-consult (Patients)Usual Care (Providers)Proactive E-consult (Providers)Total
Median65 (60 to 70)65 (60 to 70)49 (35 to 61)46 (36 to 64)64 (59 to 70)
Sex: Female, Male
Sex: Female, Male(Participants)Usual Care (Patients)Proactive E-consult (Patients)Usual Care (Providers)Proactive E-consult (Providers)Total
Female479828
Male1361231010279
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Usual Care (Patients)Proactive E-consult (Patients)Usual Care (Providers)Proactive E-consult (Providers)Total
American Indian or Alaska Native10001
Asian10315
Native Hawaiian or Other Pacific Islander20002
Black or African American897600165
White455268111
More than one race00000
Unknown or Not Reported22131835
Region of Enrollment
Region of Enrollment(Participants)Usual Care (Patients)Proactive E-consult (Patients)Usual Care (Providers)Proactive E-consult (Providers)Total
United States1401302227319
08

Study locations

7 sites
  • VA Greater Los Angeles Healthcare System
    Los Angeles, California 90073, United States
  • VA Eastern Colorado Health Care System
    Denver, Colorado 80012, United States
  • VA Connecticut Healthcare System
    New Haven, Connecticut 06111, United States
  • Washington DC VA Medical Center
    Washington D.C., District of Columbia 20422, United States
  • Atlanta VA Health Care System
    Atlanta, Georgia 30033, United States
  • Philadelphia VA Medical Center
    Philadelphia, Pennsylvania 19104, United States
  • Nashville VA Medical Center
    Nashville, Tennessee 37212, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2019 to primary completion in May 2025, 72 months.

Results were first posted in Nov 2026, 1 year 5 months after primary completion.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's 72 months is above that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 20, 2019
First posted
Feb 27, 2019
StartActual
May 21, 2019
Primary completionActual
May 31, 2025
CompletionActual
May 31, 2025
Results first posted
Nov 10, 2026
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Results
Results posted
posted Nov 10, 2026
Enrollment
270→346
Nov 10, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • Edited% of COPD care recommendations receivedCare Recommendations Received by patientsPatients of enrolled providersEnrolled ProvidersTime frame: 6 months following provider/patient appointment → Within 6 months following provider/patient appointment
Nov 10, 2026
Secondary outcomes
2 edited
What changed in the outcomes
  • EditedPatient healthHealth-related qualityQuality of lifeLifeTime frame: 6 weeks following provider/patient appointment
  • Editedother outcomeHIV provider satisfaction with specialtyProvider Satisfaction With Specialty-care supportSupportTime frame: Baseline: prior to intervention roll-out. Follow-up: after exposure to intervention (defined as having received at least 2 E-consults), up to 3 years.
Nov 10, 2026
Show all 1 update
  1. Nov 10, 2026
    Results posted
    Enrollment 270→346
    Primary outcomes 1 edited
    What changed in the outcomes
    • Edited% of COPD care recommendations receivedCare Recommendations Received by patientsPatients of enrolled providersEnrolled ProvidersTime frame: 6 months following provider/patient appointment → Within 6 months following provider/patient appointment
    Secondary outcomes 2 edited
    What changed in the outcomes
    • EditedPatient healthHealth-related qualityQuality of lifeLifeTime frame: 6 weeks following provider/patient appointment
    • Editedother outcomeHIV provider satisfaction with specialtyProvider Satisfaction With Specialty-care supportSupportTime frame: Baseline: prior to intervention roll-out. Follow-up: after exposure to intervention (defined as having received at least 2 E-consults), up to 3 years.
    + 4 other changes: verification date, oversight details, index terms and registry notes

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT03856879
Lead sponsor
Seattle Institute for Biomedical and Clinical Research
Collaborators
VA Puget Sound Health Care System, Washington D.C. Veterans Affairs Medical Center, VA Eastern Colorado Health Care System, University of Colorado, Denver, VA Greater Los Angeles Healthcare System, Atlanta VA Medical Center, Yale University, VA Connecticut Healthcare System, Corporal Michael J. Crescenz VA Medical Center, VA Tennessee Valley Health Care System
Responsible party
Sponsor
First posted
Feb 27, 2019
Start date
May 21, 2019
Primary completion
May 31, 2025
Completion
May 31, 2025
Results posted
Nov 10, 2026
Last update
Nov 10, 2026

Study contacts

David H. Au, MD, MS
principal investigator · VA Puget Sound Health Care System
Kristina A. Crothers, MD
principal investigator · VA Puget Sound Health Care System
Christian D. Helfrich, PhD, MPH
principal investigator · VA Puget Sound Health Care System

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion